

(<http://aphanet.org>)

[Home](#) > First generic version approved

Generic Name:

Fondaparinux sodium injection

Trade Name:

generics

Company:

Dr. Reddy's; Alchemia

Notes:

Dr. Reddy's Laboratories and Alchemia Limited announced FDA approval of fondaparinux sodium injection, the first and only bioequivalent generic version of GlaxoSmithKline's Arixtra. The approval includes the 2.5 mg/0.5 mL, 5.0 mg/0.4 mL, 7.5 mg/0.6 mL, and 10 mg/0.8 mL doses of fondaparinux in prefilled color-coded, single-dose syringes with an automatic needle safety device. This new generic will be manufactured using a patented process developed by Alchemia. According to a company [press release](#), competition is likely to be limited for the foreseeable future because of the complexity involved in manufacturing this generic product.

Medication Monitor Categories:

[Supplemental Approvals](#)

Use:

Prophylaxis of deep vein thrombosis (DVT), treatment of DVT, and treatment of acute pulmonary embolism

Source URL: <http://aphanet.org/supplemental-approvals/first-generic-version-approved>